Cibus Inc Cuts Expenses and Secures $200M Rice Partnerships Despite $31.9M Q4 Loss
Cibus posted a Q4 net loss of $31.9M vs $25.8M year-earlier, with $1.1M revenue and $9.9M cash after a $22.3M January public offering. It cut R&D to $9.4M and SG&A to $5.1M, secured seven rice customers over $200M in potential royalties, and won UK/EU support for its gene-editing platform.
1. Q4 Financial Performance
Cibus recorded a net loss of $31.9 million for the quarter, widening from $25.8 million a year earlier, on just $1.1 million revenue. The company ended December with $9.9 million in cash following a $22.3 million public offering in January to bolster its balance sheet.
2. Operational Cost Cuts
In 2025, operating expenses dropped by approximately $10 million as R&D spending decreased to $9.4 million from $12.4 million and SG&A fell to $5.1 million from $6.8 million. These measures aim to extend the company’s financial runway and improve path to profitability.
3. Partnerships and Regulatory Advances
Cibus secured seven rice trait customers representing over $200 million in potential annual royalties and received its first sustainable ingredients payment. It also partnered with the UK government on farming innovation and leveraged new EU genomic techniques legislation to accelerate its gene-editing platform commercialization.